Emma Ballard

Emma Ballard

Auto-generated profile, based on publicly available information

Emma Ballard

QIMR Berghofer Medical Research Institute

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AMAlexandra Mowat
Alexandra Mowat
CMChristopher Maher
Christopher Maher
EBEmma Ballard
Emma Ballard

1 October 2019 in Journal of Hospital Infection
Verified
Journal Article
Closed access
RSR.E. Stockwell
R.E. Stockwell
EBE.L. Ballard
E.L. Ballard
POP. O'ROurke
P. O'ROurke
Knibbs LukeKnibbs Luke
Knibbs Luke
LMLidia Morawska
Lidia Morawska
SBS.C. Bell
S.C. Bell

20 January 2015 in Liver International
Verified
Journal Article
Closed access
PDF file
KFKevin J. Fagan
Kevin J. Fagan
CPCarel Pretorius
Carel Pretorius
LHLeigh U. Horsfall
Leigh U. Horsfall
KIKatharine Irvine
Katharine Irvine
UWUrs Wilgen
Urs Wilgen
EPElizabeth E. Powell
Elizabeth E. Powell

1 June 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
NHNir Haya
Nir Haya
KBKaven Baessler
Kaven Baessler
CCCorina Christmann-Schmid
Corina Christmann-Schmid
RTRenaud de Tayrac
Renaud de Tayrac
VDViviane Dietz
Viviane Dietz
CMChristopher F. Maher
Christopher F. Maher

12 August 2020 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
JSJeremy Cheuk Kin Sin
Jeremy Cheuk Kin Sin
LKLillian King
Lillian King
EBEmma Ballard
Emma Ballard
SLStacey Llewellyn
Stacey Llewellyn
KLKevin B. Laupland
Kevin B. Laupland
ATAlexis Tabah
Alexis Tabah
Hypophosphatemia is reported in up to 5% of hospitalized patients and ranges from 20% to 80% in critically ill patients. The consequences of hypophosphatemia for critically ill patients remain controversial. We evaluated the effect of hypophosphatemia on mortality and length of stay in intensive care unit (ICU) patients. MEDLINE, EMBASE, Cochrane Library (Reviews and Trials), and PubMed were searched for articles in English. The primary outcome was mortality and secondary outcome was length of stay. The quality of evidence was graded using a modified Newcastle-Ottawa Scale. Our search yielded 828 articles and ultimately included 12 studies with 7626 participants in the analysis. Hypophosphatemia was associated with increased hospital length of stay (2.19 days [95% CI, 1.74-2.64]) and ICU length of stay (2.22 days [95% CI, 1.00-3.44]) but not mortality (risk ratio: 1.13 [95% CI, 0.98-1.31]; P = .09). Hypophosphatemia in ICU was associated with increased hospital and ICU length of stay but not all-cause mortality. Hypophosphatemia appears to be a marker of disease severity. Limited number of available studies and varied study designs did not allow for the ascertainment of the effect of severe hypophosphatemia on patient mortality.

20 December 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JMJames S. McCarthy
James S. McCarthy
TRThomas Rückle
Thomas Rückle
SESuzanne L. Elliott
Suzanne L. Elliott
EBEmma Ballard
Emma Ballard
KCKatharine A. Collins
Katharine A. Collins
JMJörg Johann Möhrle
Jörg Johann Möhrle
Artefenomel and DSM265 are two new compounds that have been shown to be well tolerated and effective when administered as monotherapy malaria treatment. This study aimed to determine the safety, pharmacokinetics, and pharmacodynamics of artefenomel and DSM265 administered in combination to healthy subjects in a volunteer infection study using the Plasmodium falciparum-induced blood-stage malaria model. Thirteen subjects were inoculated with parasite-infected erythrocytes on day 0 and received a single oral dose of artefenomel and DSM265 on day 7. Cohort 1 (n = 8) received 200 mg artefenomel plus 100 mg DSM265, and cohort 2 (n = 5) received 200 mg artefenomel plus 50 mg DSM265. Blood samples were collected to measure parasitemia, gametocytemia, and artefenomel-DSM265 plasma concentrations. There were no treatment-related adverse events. The pharmacokinetic profiles of artefenomel and DSM265 were similar to those of the compounds when administered as monotherapy, suggesting no pharmacokinetic interactions. A reduction in parasitemia occurred in all subjects following treatment (log10 parasite reduction ratios over 48 h [PRR48] of 2.80 for cohort 1 and 2.71 for cohort 2; parasite clearance half-lives of 5.17 h for cohort 1 and 5.33 h for cohort 2). Recrudescence occurred in 5/8 subjects in cohort 1 between days 19 and 28 and in 5/5 subjects in cohort 2 between days 15 and 22. Low-level gametocytemia (1 to 330 female gametocytes/ml) was detected in all subjects from day 14. The results of this single-dosing combination study support the further clinical development of the use of artefenomel and DSM265 in combination as a treatment for falciparum malaria. (This study has been registered at ClinicalTrials.gov under identifier NCT02389348.)